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1 GENERAL PART   
1.1 INTRODUCTION 
In clinical and forensic toxicology, screening and quantification of different classes of drugs is 
a very important task to evaluate different topics e.g. chemical-induced diseases, acute 
intoxication or poisoning, toxic effects, driving under the influence of drugs, drug-induced 
impairment of legal responsibility, committing a crime under the influence of drugs, and also 
death caused by intoxication.1-6 In these fields, the following drugs are usually involved: drugs 
of abuse such as amphetamines, designer drugs, opiates or cocaine, synthetic opioids, 
alkaloids such as atropine, and most recently, new synthetic drugs such as synthetic 
cannabinoids or phenethylamines, psychotropic drugs (e.g. antidepressants and 
neuroleptics), and benzodiazepines or Z-drugs.7,8 In addition, several cases of sudden death 
associated with phosphodiesterase type 5 (PDE-5) inhibitors often in combination with heart 
diseases have been pulished.9  
Opiates (e.g. morphine and derivatives) or synthetic opioids (e.g. tilidine) can cause sedative 
and analgesic effects but also some side effects such as sedation, respiratory depression, 
constipation, and a strong sense of euphoria.10 The combination of these drugs with alcohol 
or benzodiazepines increases the rates of adverse events, intoxication, and death of 
patients.11 
Over the last years cannabis users shifted to the consumption of herbal mixtures including 
synthetic cannabinoids as a more or less legal alternative to cannais.12 Synthetic 
cannabinoids have the same, if not stronger, effects than cannabis.12 The production of these 
herbal mixtures is mostly uncontrolled, thus, declaration of the ingredients is often 
insufficient, which can lead to problems. Consumers often do not know, which compounds 
have been added to the mixture.13 Studies of synthetic cannabinoids over the last years show 
the importance of those substances in post-mortem forensic toxicology. Acute effects of 
synthetic cannabinoids as well as chronic exposure have to be considered.13 
Phenethylamine containing two methoxy groups at positions 2 and 5 of the benzene ring and 
a substituted 4 position interact effectively with serotonin receptors, and act as agonists of 
the 5-HT2A receptor.14 This group of substances was named 2C family y Alexander 
Shulgin.14  
Benzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid 
(GAA), which may lead to sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxing 
effects.10 These effects may result in slow and uncertain reflexes and can therefore influence 
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driving aility.15 In combination with alcohol and other CNS active substances, they can lead to 
severe poisonings or even death.11,16 Three groups of benzodiazepines are known; short- 
(e.g. triazolam), intermediate- (e.g. flunitrazepam), or long-acting (e.g. nordazepam) 
enzodiazepines.16 The so-called Z-drugs (e.g. zaleplon), also called non-benzodiazepines 
have a pharmacological activity similar to benzodiazepines. Z-drugs have demonstrated 
efficacy in treating sleep disorders as they have less influence on the sleep architecture but 
also known producing side effect such as pronounced amnesia and more rarely 
hallucinations, especially when used in large doses.17 
Antidepressants are psychotropic drugs that were mainly used for treatment of depression, in 
obsessive-compulsive, panic, generalized anxiety disorder, chronic pain, lethargy, insomnia 
as well as in post-traumatic stress disorder.18 In the group of antidepressants, several sub-
groups are known such as tricyclic antidepressants (e.g. amitriptyline), tetracyclic 
antidepressants (e.g. mianserin), selective serotonin reuptake inhibitors (SSRIs, e.g. 
citalopram) or selective norepinephrine reuptake inhibitors (SNRIs, e.g. milnacipran), and 
monoamine oxidase A inhibitors (e.g. moclobemide).19,20 In combination with substances like 
alcohol, benzodiazepines, neuroleptics, or opioids, the respiratory depressant effect can 
increase and cause acute poisonings.10 
Neuroleptics, also named antipsychotics, are primarily used to treat psychosis such as 
hallucinations but also for the treatment of schizophrenia and the manic episodes of bipolar 
disorder.18 Neuroleptics, especially the classic ones, can show severe side effects such as 
extrapyramidal symptoms and cardiovascular complications such as arrhythmia or ventricular 
fibrillation.20,21 These side effects can result in sudden death, especially when overdosed. 
Therefore, neuroleptics play an important role in clinical and forensic toxicology.22,23 
Moreover, besides the central nervous system (CNS) effects, the vegetative side effects, 
such as accommodation disorder or hypotonic dysregulation can impair the driving ability. 
One can differentiate between first-generation neuroleptics such as droperidol and second-
generation neuroleptics such as clozapine.24 The latter produce less extrapyramidal 
disabilities such as parkinsonoid than first-generation.24 
 
In clinical and forensic toxicology, the analytical strategy includes screening followed by 
quantification.3,4 Screening for the above-mentioned drug classes is important and for some 
of them (e.g. benzodiazepines, antidepressants, and neuroleptics), quantification is also 
demanded to clarify different topics as already discussed above.4 As the background of the 
individual cases as well as the profile of requirements may be very different, the toxicologist 
has to choose the best suitable biosample and method of analyses to clarify the questions.4 
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The best biosample to show the acute influence of a drug on the body is blood, which 
consists of cellular particles such as erythrocytes, leukocytes, thrombocytes.26 Blood plasma 
includes clotting factors and results from centrifugation of blood after treatment with 
anticoagulants. Plasma without clotting factors is named “serum” and contains less 
fibrinogen but more phosphate and sodium ions.26 However, depending on sampling, 
storage, and/or type of analysis, whole blood, plasma, or serum are used for analysis. For 
the interpretation of drug concentrations in blood comprehensive blood level lists can be 
helpful.27,28 For abstinence programs in a rehabilitation center or for driving ability surveys, 
blood seems not to be the best suitable biosample because not the acute influence but the 
consumption behavior is of interest.29,30 For this question, urine or hair samples are better 
biosamples because drugs can be detected even days or up to weeks/months after the 
intake.29,30 Concentrations of analytes or their metabolites in urine can be higher than in 
blood, so that screening for them may give better results.4 The collection of urine samples is 
accompanied by the invasion of the privacy as laboratory stuff has to attend the sampling 
site.29 To circumvent this invasion of the privacy, hair samples can be collected.29 It has been 
proposed that drugs are incorporated into hair by binding to intracellular components as 
melanins, lipids, and proteins, and therefore, provide a historical profile depending on the hair 
length.31 As shown elsewhere, hair analysis can allow to distinguish between acute, chronic, 
and one-time substance use.32,33 In post mortem cases, different biosamples are usually 
available.34 To determine the link between compound concentrations and effect, whole blood 
is the main post mortem biosample, however, post mortem redistribution as well as instability 
of drugs have to be kept in mind for interpretation of post mortem analyte findings.25,35 In post 
mortem cases where blood cannot be obtained, tissues such as liver or kidney are possible 
biosamples for analysis. 
After collection of the best suitable biosample, it has to be analyzed by suitable 
approaches.4,6 The first step is to find the right extraction procedure for each biosample.4 For 
whole blood, plasma, serum, and post mortem blood, methods using liquid-liquid-extraction, 
solid-phase-extraction, dilution, and protein precipitation have been published.34,36-46 Urine 
workup can be performed by enzymatic hydrolysis of the conjugates and liquid-liquid-
extraction,47 enzymatic hydrolysis and solid-phase extraction,37 solid-phase extraction without 
cleavage of conjugates,36 or dilution.48 For hair samples, methods using methanolic 
extraction,31 microwave-assisted hydrolysis and microwave extraction,49 extraction with 
phosphate buffer,50 extraction with acetonitrile51 and solid-phase extraction34,52 were 
published. For homogenized liver tissue, incubation with Subtilisin, followed by an extraction 
with butyl chloride was published.53 Laloup et al. published one single extraction for three 
biosamples, blood, urine, and hair.36 Maurer et al. published a work-up procedure for plasma, 
gastric content, and urine using diethyl ether-ethyl acetate (1:1).54 Different extraction 
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procedures for every biosample and every drug group cost time and resources, therefore one 
extraction procedure for all above-mentioned drug classes and biosamples should be found 
to analyze each biosample in one analytical run. Different methods have been published for 
screening and quantification of different drug classes. Over the last years, more and more 
multi-analyte approaches were developed using different techniques, e.g. immunochemical 
analysis, gas chromatography-mass spectrometry (GC-MS), and/or liquid chromatography-
mass spectrometry (LC-MS).7,12,19,23,34,36,38-48,56-63 
The results of toxicological analyses and their interpretation can have serious legal 
consequences. Therefore, a screening or quantification method has to be validated and the 
quality of the method has to be controlled strictly and constantly by internal and external 
quality control. For screening and quantification methods, Peters et al.64,65 described 
extensively, which parameters should be included in validation experiments for quantitative 
methods; selectivity, calibration model (linearity), recovery, matrix effects, stability, accuracy 
(bias), precision (repeatability, intermediate precision), the limit of detection (LOD) and lower 
limit of quantification (LLOQ). When using LC-MS(/MS), matrix effects, ion suppression and 
enhancement may cause problems and therefore has to be checked for.38,66   
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2 AIMS AND SCOPES 
As mentioned above, a lot of procedures for screening and quantification of different drug 
classes using liquid chromatography-mass spectrometry (LC-MS/MS) or gas 
chromatography-mass spectrometry (GC-MS) in different biosamples have been published 
but none of them showed a screening method for over 100 drugs in eight different matrices, 
or validated quantification of various drugs in the three most commonly used biosamples, 
whole blood, plasma, and serum.  
 
Therefore, the aims of the present dissertation are: 
 
   To develop a simple extraction and LC-MS/MS approach for screening and 
identification of over 100 analytes in eight different matrices 
 
  To develop and validate multi-analyte LC-MS/MS approaches for quantification of 33 
antidepressants, 33 neuroleptics, and 19 benzodiazepines including Z-drugs in whole 
blood, plasma, and serum 
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3 PUBLICATION OF THE RESULTS 
The results of the studies were published in the following papers: 
3.1 A SIMPLE EXTRACTION AND LC-MS/MS APPROACH FOR THE SCREENING 
AND IDENTIFICATION OF OVER 100 ANALYTES IN EIGHT DIFFERENT 
MATRICES. (DOI 10.1002/DTA.1657)67 
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3.2 DETECTION AND QUANTIFICATION OF BENZODIAZEPINES AND Z-DRUGS IN 
HUMAN WHOLE BLOOD, PLASMA, AND SERUM SAMPLES AS PART OF A 
COMPREHENSIVE MULTI-ANALYTE LC-MS/MS APPROACH. (DOI 
10.1007/S00216-013-7513-X)68 
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3.3 QUANTIFICATION OF 33 ANTIDEPRESSANTS BY LC-MS/MS-COMPARATIVE 
VALIDATION IN WHOLE BLOOD, PLASMA, AND SERUM. (DOI 
10.1007/S00216-014-8019-X)69 
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3.4 DEVELOPMENT AND VALIDATION OF A MULTI-ANALYTE LC-MS/MS 
APPROACH FOR QUANTIFICATION OF NEUROLEPTICS IN WHOLE BLOOD, 
PLASMA, AND SERUM. (10.1002/DTA.1923)70 
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4 DISCUSSION AND CONCLUSIONS 
 
Development including full validation of the multi-analyte approaches has been published in 
four original papers presented in chapters 3.1-4 of this thesis.68-70  
 
The multi-analyte multi-biosample approach (3.1) allowed for the first time screening and 
identification of 130 analytes from the most important drug classes in forensic toxicology in 
eight different biosamples. Only one single work-up approach, one column, one gradient, and 
one scheduled multi-reaction mode (MRM) method was used. The described extraction 
procedure was preferred over that described by Laloup et al.,36 who already published one 
single extraction procedure for three biosamples, blood, urine, and hair, because all validated 
GC-MS procedures in the authors’ laboratory, using also this extraction procedure, should be 
used in combination with the presented approach. For identification, three MRM transitions, 
the retention times as well as the enhanced product ion (EPI) spectra (if intensity > 5000 cps) 
were used. Some analytes needed three MRM transitions for the certain identification. For 
the application of the established plasma extraction procedure,54 it had to be adjusted to pH 
7.4 using Sörensen Buffer because of different pH values in the different biosamples such as 
whole blood, serum, and post mortem blood. As shown by the limit of detection (LOD) or 
recovery results, this extraction approach, which should also be used for liver tissue, gastric 
content, hair samples, and urine samples, was stretched to its limits especially for urine 
samples. The LODs in whole blood, plasma, serum, and post mortem blood should be lower 
than the lowest therapeutic concentration described in comprehensive blood level lists.28,27 
For 29 of 130 analytes, especially designer drugs, no therapeutic concentrations were found 
in those lists. For six out of the 101 remaining analytes, the LODs were in the range of the 
lowest therapeutic concentrations, for 16 analytes, in the therapeutic range, and for three 
analytes, in the range of the highest therapeutic concentrations.27,28 In addition, the LODs for 
some analytes found in whole blood, plasma, and serum were not the same as in post-
mortem blood and liver tissue. The LOD results were comparable to other multi-analyte 
methods for the respective biosample.41,42,47-52,63 Recovery, matrix effect, and process 
efficiency tests were performed for 30 typical analytes covering each drug class and the 
whole retention window. Amitriptyline showed higher RE values in whole blood, post-mortem 
blood and liver tissue in comparison to the values found in plasma and serum. These results 
were reproducible but not explainable yet. A t-test was performed to compare the matrix 
effect (ME) values between plasma and the other mentioned biosamples. ME values for 
plasma vs. serum (2/30) and plasma vs. post-mortem blood (3/30) differed not significantly, 
but significant differences were found for plasma vs. whole blood (9/30), plasma vs. liver 
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tissue (11/30), plasma vs. hair (14/30), and plasma vs. urine samples (19/30). The significant 
differences for the ME values between the different biosamples resulted from the different 
endogenous components of the biosamples. Whole blood includes erythrocytes and 
leukocytes and coagulates within a few minutes into a half-solid mass named coagulum, 
which includes modified plasma, blood cells, and fibrin.26 Serum which contains less 
fibrinogen than plasma but more phosphate and sodium ions is formed after centrifugation. If 
whole blood is treated with anticoagulants, plasma is formed after centrifugation.26 Liver 
tissue includes hepatocytes, whole blood, fat tissue and bile.71 Especially the presence of fat 
impeded the extraction of some analytes. Urine includes water, urea, electrolytes, creatinine 
and sometimes proteins.71 Hair consists mostly of keratin, after the extraction procedure 
often fat arrears were detected, which could impede the extraction of some analytes. 
 
As mentioned before, in clinical and forensic toxicology, the analytical strategy includes 
screening and identification followed by quantification.4 
Therefore, for the three largest groups of drugs out of the previous described multi-analyte 
multi-biosample approach (benzodiazepines and Z-drugs (3.2), antidepressants (3.3), 
neuroleptics (3.4)) and for the most common biosamples in the author´s laboratory (whole 
blood, plasma, and serum), an LC-MS/MS approach for quantification was developed and 
fully validated. Special focus was placed on the matrix effect, recovery, and process 
efficiency and their statistical differences in-between the different biosamples. The validation 
consisted of selectivity, recovery, matrix effects, process efficiency with statistical data 
evaluation, cross talk, calibration model, accuracy, precision, processed sample stability, 
freeze/thaw stability, bench top stability, lower limit of quantification (LLOQ), limit of 
detection, and applicability in whole blood, plasma, and serum according to national 
guiudelines.64,65 Furthermore, for the group of antidepressants, comparative validation 
between these three biosamples were done. For all analytes and biosamples a full six-point 
calibration was performed.  
The LC-MS/MS method described in 3.2 allowed accurate and precise quantification of 16 
benzodiazepines in whole blood, for 18 benzodiazepines in plasma, and for 17 
benzodiazepines in serum. In 2015, Mata et al. also published an LC-MS/MS method for 
quantification of benzodiazepines in six different matrices using weak anion exchange tips 
with lower LOD results than presented in this dissertation, but no statistical data evaluation 
was performed to compare the RE, ME or PE values between the different biosamples.44 In 
contrast, in our study, statistical data evaluation was performed to compare the RE values. 
Especially tetrazepam showed significant differences for RE values. The RE value in plasma 
samples was 235% compared to 78% (serum) and 85% (whole blood). The enhanced signal 
of tetrazepam in plasma samples compared to the signal in whole blood and serum samples 
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led to the conclusion that the tetrazepam concentration in a plasma sample could not be 
calculated by the serum or whole blood calibration curve. For other analytes of the 
benzodiazepine group, cross calibration seemed to be possible, e.g for bromazepam where 
no significant differences were found for the RE values. For benzodiazepines, no selectivity 
problems were observed, in contrast to the approach for antidepressants (3.3), where in the 
MRM transitions of amoxapine in plasma and serum samples an interfering signal caused by 
the internal standard was detected. As the interfering signal was only the signal of the 
qualifier, it was irrelevant for quantification.  
Also for the group of antidepressants (3.3), a fully validated LC-MS/MS approach was 
developed for whole blood, plasma, and serum. In addition, accuracy and precision were 
determined for the first time for each biosample calculated over a calibration curve in the 
corresponding biosample as well as over a calibration curve made in another biosample. 
Cross-calibration for analytes in whole blood and serum calculated over a calibration curve 
made in plasma, for analytes in whole blood and plasma calculated over a calibration curve 
made in serum provided better results than analytes in plasma and serum calculated over a 
calibration curve made in whole blood. With the exception of three analytes in whole blood, 
two analytes in plasma, and five analytes in serum, all antidepressants fulfilled the validation 
criteria in the three biosamples. The assumption that calculation of benzodiazepines should 
only be done in the same biosample has been confirmed for antidepressants after cross-
calibration experiments.  
For 25 neuroleptics in whole blood, 19 in plasma, and 17 in serum (3.4), this LC-MS/MS 
method allowed accurate and precise quantification. In contrast to the approach for 
benzodiazepines and antidepressants, ME values for plasma vs. serum differed more 
significantly than between plasma vs. whole blood or serum vs. whole blood. A reason for 
that could not be found so far. No significant enhancement or suppression of co-eluting 
analytes from the same drug class was observed for the analyte pairs: 
aripiprazole/levomepromazine, benperidol/droperidol, buspirone/risperidone, 
chlorpromazine/perphenazine, chlorprothixene/zotepine, clozapine/ziprasidone, 
flupentixol/fluspirilene, pimozide/sertindole, and pipamperone/promethazine. Remane et al.42 
published significant enhancement or suppression for four analyte pairs using APCI 
(atmospheric pressure chemical ionization), so therefore separate spiking solutions for 
calibrators and QCs samples were prepared, which is time- and cost-intensive. In the 
presented method using ESI, one spiking solution for all analytes could be used. During 
three freeze/thaw cycles, all analytes were stable with exception of chlorprothixene, 
fluspirilene, and olanzapine. This is in accordance with already described. 23,42,45 As 
expected, in contrast to Kirchherr et al.,19 who used a more sensitive apparatus, our LLOQs 
- 13 - 
 
are not as low as there published LLOQs. In summary, the three multi-analyte multi-
biosample approaches (3.2-4) fulfilled the requirements for a validated assay for 
quantification of most of the analytes. Drug levels of authentic cases determined in an 
external laboratory with already published methods41,42 could be confirmed with the new 
approaches and external quality control samples of proficiency tests were measured 
successfully. Thus, the method could be included into the forensic routine. However, the use 
of calibration curves, made with one type of biosample for quantification in other biosamples 
remains an unsolved problem. Regarding the fact that a lot of analytes with different 
chemical structures have been implemented in this multi-analyte multi-biosample approach, 
compromises concerning recovery, accuracy and precision and LOD had to be made in 
some cases. 
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6 SUMMARY 
In the present dissertation, the development of a multi-analyte multi-biosample LC-MS/MS 
approach with simple extraction is described for the screening and identification of over 100 
analytes in eight different matrices. The analytes were extracted with one single liquid-liquid 
work-up approach from eight different matrices and separated with one column and one 
multi-reaction mode (MRM) method. In addition, three methods for quantification of 19 
benzodiazepines including Z-drugs, 33 antidepressants, and 33 neuroleptics in three 
different matrices were developed, fully validated, and the results evaluated concerning cross 
calibration. The present studies showed that matrix effects and recovery results in different 
biosamples have an influence on the cross calibration between these biosamples. The 
applicability of the presented method was shown using authentic human samples and 
external quality control samples. Especially for the group of antidepressants, it was shown 
that cross-calibration between different biosamples could only be used for some analytes. 
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7 ZUSAMMENFASSUNG 
Im Rahmen dieser Dissertation wurde eine LC-MS/MS Methoden für schnelles Screening 
von rund 100 Arzneistoffen und Drogen in acht verschiedenen Matrizes entwickelt. Für diese 
Vielzahl an Substanzen und Untersuchungsmaterialien wurden ein einziger 
Extraktionsansatz sowie eine analytische Säule und eine MRM-Methode zur Trennung 
verwendet. Zusätzlich wurden für die Quantifizierung von 19 Benzodiazepinen einschließlich 
sogenannter Z-Drugs, 33 Antidepressiva und 33 Neuroleptika in drei verschiedenen 
Blutpräparationen neue LC-MS/MS Methoden entwickelt, nationalen Richtlinien validiert und 
die Ergebnisse bezüglich Kreuz-Kalibration ausgewertet. Hierbei zeigte sich, dass Probleme 
mit Matrixeffekten und der Extraktionsausbeute bei einigen Substanzen in verschiedenen 
Untersuchungsmaterialien einen Einfluss auf die Kreuz-Kalibrierung zwischen diesen 
Untersuchungsmaterialien haben. Die Anwendbarkeit des vorgestellten Verfahrens wurde 
anhand authentischer Untersuchungsproben und externen Qualitätskontrollproben bestätigt. 
Vor allem für die Substanzklasse der Antidepressiva wurde gezeigt, dass die Kreuz-
Kalibrierung zwischen verschiedenen biologischen Matrizes nur für ausgewählte Substanzen 
in Betracht gezogen werden kann. 
